Abstract:Abstract Background In 2021, the United States (US) FDA issued a label update limiting the use of Janus kinase inhibitors (JAKi) to after tumour necrosis factor inhibitors (TNFi). We examined the rate of steroid use and treatment failure among patients (pts) with ulcerative colitis (UC) initiating a JAKi vs TNFi using data from a US claims database. Methods A database of adjudicated medical and pharmacy claims (IQVIA PharMetrics Plus; 2007–2022) was utilised to select pts with UC starting either a new JAKi/TNFi on/after 30 May 2018. Pts were followed from index date to the end of the study period, event of interest or treatment switch (whichever came first). The study assessed steroid use within 90 days of index date, and also treatment failure over the first 6 months after index date, defined as a composite of any: hospitalisation related to UC/colectomy (inpatient/emergency room)/switch to another advanced treatment (AT)/steroid use ≥90 days after index treatment initiation. Individual components of treatment failure were also analysed. Stabilised inverse probability treatment weights (sIPTW) were calculated using 19 confounders. Cox proportional hazards models with sIPTW were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Additional analyses stratifying by AT-naïve vs AT-experienced pts were conducted. Results In total, 6019 pts were included; 763 initiated a JAKi and 5256 a TNFi. More pts initiating a TNFi had prior use of non-biologic conventional treatments and were on concomitant conventional treatments at index date, compared with pts initiating a JAKi. Prior AT was more prevalent among JAKi- (74.3%) vs TNFi- (15.3%) treated pts; baseline steroid use was generally similar across groups (Table). Overall, there was a significantly lower risk of steroid use within 90 days in pts initiating a JAKi vs a TNFi (HR 0.75 [95% CI 0.65, 0.87]), and among AT-naïve and AT-experienced pts (HR 0.79 [95% CI 0.64, 0.97] and HR 0.69 [95% CI 0.59, 0.82], respectively; Figure a). There was a significantly lower risk of treatment failure with JAKi vs TNFi (HR 0.80 [95% CI 0.68, 0.94]; Figure b). A significantly lower risk of steroid use ≥90 days was found amongst JAKi- vs TNFi-treated pts overall and within AT-naïve and AT-experienced subgroups (Figure b–d). Conclusion In this large US-based claims analysis, pts with UC treated with a JAKi had significantly less steroid use than those treated with a TNFi; this was consistent in AT-naïve and AT-experienced pts. Limitations included confounding of factors uncontrollable in claims data and inherent bias due to approved use of JAKi in the US only in pts with inadequate response to TNFi. Study sponsored by Pfizer. Medical writing support provided by C Duncan, CMC Connect; funded by Pfizer.

P789 Impact of risk factors for Janus kinase inhibitor use identified by the Pharmacovigilance Risk Assessment Committee on the safety and efficacy of ozanimod in patients with moderately to severely active ulcerative colitis

P637 Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA–exposed, advanced therapy–naive, immunomodulator-naive patients with ulcerative colitis: a post hoc analysis of True North

P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)

P687 Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a Phase 2/3 study (J-True North)

P567 Impact of recent thiopurine use on ozanimod safety in patients with ulcerative colitis: a post hoc analysis of the phase 3 True North study

DOP16 Safety of long-term ozanimod treatment for up to 4 years in patients with moderately to severely active Ulcerative Colitis: an interim analysis of the True North open-label extension

P790 Assessment of steroid use in patients with active ulcerative colitis who initiated a new Janus kinase inhibitor or tumour necrosis factor inhibitor using data from a United States claims database

P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study

P850 Symptomatic effectiveness of ozanimod in routine clinical care of ulcerative colitis: an interim analysis of the multicentre, prospective, noninterventional COLIBRI study

DOP78 Efficacy of ozanimod by patient response trajectory subgroups identified using group-based trajectory modelling: a post hoc analysis of the phase 3 True North study

S1476 Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension

S1342 Impact of Baseline Disease Duration on Ozanimod Efficacy in Patients With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 True North Study

Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses

P514 Beyond the First Attempt: A Multi-Centre UK Analysis of Second JAK Inhibitor Use in Ulcerative Colitis

Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis

P653 Impact of ozanimod on type III collagen turnover biomarkers and the association with ozanimod efficacy in patients with moderately to severely active ulcerative colitis: Results from the phase 3 True North study

Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis

P706 Tofacitinib in Moderate to Severe Ulcerative Colitis patients naïve to biological therapy: A prospective real world analysis of efficacy and safety

Clinician’s Guide to Using Ozanimod for the Treatment of Ulcerative Colitis

Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis